CCMI
NBIX icon

Creative Capital Management Investments’s Neurocrine Biosciences NBIX Stock Holding History

Creative Capital Management Investments’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.2K Buy
+19
New +$2.82K ﹤0.01% 588

Other funds holding NBIX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PBBUPS
PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
AB
Amalgamated Bank New York $14.5B AUM 44.3% 1-Year Est. Return

Creative Capital Management Investments's NBIX Position: Q2 2026 in Review

Creative Capital Management Investments opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 19 shares worth $3.2K. The stake represents ﹤0.01% of the portfolio and ranks #588 among its holdings.

166 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Creative Capital Management Investments held 19 shares of Neurocrine Biosciences worth $3.2K as of Q2 2026.
  • Neurocrine Biosciences was a new Creative Capital Management Investments position in Q2 2026.
  • Neurocrine Biosciences made up ﹤0.01% of Creative Capital Management Investments's portfolio in Q2 2026, its #588 holding.
  • 166 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Creative Capital Management Investments's 13F filing for Q2 2026, filed 24 Jul 2026.